Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ROFLUMILAST 250 MCG TABLET

Roflumilast
$1.9621per EA

Strength

250 ug/1

Manufacturer

Major Pharmaceuticals

NDC

00904749371

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA208256

On Market Since

10/27/2025

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price History

1W

0.0%

1M

-8.5%

3M

-14.0%

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

-14.3%

Generic Alternatives

4 alternatives • Same active ingredient

ROFLUMILAST 250 MCG TABLET
Generic
67877073093•Ascend Laboratories, LLC
$1.9621
ROFLUMILAST 250 MCG TABLET
Generic
31722067636•Camber Pharmaceuticals Inc.
$1.9621
ROFLUMILAST 250 MCG TABLET
Generic
72205020132•Novadoz Pharmaceuticals LLC
$1.9621
ROFLUMILAST 250 MCG TABLET
Generic
68382062431•Zydus Pharmaceuticals (USA) Inc.
$1.9621

Related Drugs

Same classification

ROFLUMILAST 500 MCG TABLET
Generic
43547000503•Solco Healthcare US LLC
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
43547000509•Solco Healthcare US LLC
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
59651027530•Aurobindo Pharma Limited
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
59651027590•Aurobindo Pharma Limited
$0.3187
per EA
ROFLUMILAST 250 MCG TABLET
Generic
42571036983•Micro Labs Limited
$1.9621
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy